CI

At a glance

ClinicalIndex Comparison Record
Phase 1Completed· 42 enrolled
Drug / intervention
Pembrolizumabbiological
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT02180061
NCT02180061Phase 1Completed
CompareCT.gov

Phase Ib Study of MK-3475 in Subjects With Advanced Melanoma

Merck Sharp & Dohme LLC·interventional·Posted Jul 2, 2014·Updated Mar 31, 2020

In Brief

A Phase 1 clinical trial evaluating Pembrolizumab for Melanoma. Completed, enrolled 42 participants.

Detailed Summary

This study will assess the safety, tolerability, and efficacy of every-3-week dosing (Q3W) of pembrolizumab (MK-3475) in participants with advanced melanoma; participants may receive pembrolizumab for up to 2 years if deriving clinical benefit. The primary study hypothesis is that treatment with single agent pembrolizumab will result in a clinically meaningful overall response rate.

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsMelanoma
Countries--
Collaborators--

Timeline

Phase 1CompletedFinished
201520162017201820192020202120222023202420252026
First PostedJul 2, 2014
Enrollment StartJul 15, 2014
Primary CompletionAug 31, 2017
TodayJul 2, 2026
Enrollment to primary: 3.1 yearsPosted 12 years ago

Interventions

Pembrolizumabbiological

IV infusion